Keywords: مهارکننده کالسیروئین موضعی; AD; atopic dermatitis; AUC24; area under the concentration-time curve from 0 to 24Â h; cAMP; cyclic adenosine monophosphate; CMC; carboxymethylcellulose; ECAC; Executive Carcinogen Advisory Committee; ICH; International Conference on Harmonization; IgE; i
مقالات ISI مهارکننده کالسیروئین موضعی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهارکننده کالسیروئین موضعی; Atopic dermatitis; topical treatments; emollients; plaque model; topical calcineurin inhibitor; topical steroids; psoriasis; biomarkers; AD; Atopic dermatitis; DC; Dendritic cell; LC; Langerhans cell; TAA; Target Area Assessment; TCI; Topical calcineurin
Keywords: مهارکننده کالسیروئین موضعی; Atopic dermatitis; Microbiome; Immune dysregulation; Skin barrier; Proactive treatment; Residual disease genomic profile; Intrinsic atopic dermatitis; Extrinsic atopic dermatitis; AD; Atopic dermatitis; AL; Atopic lesional; AMP; Antimicrobial peptide; ANL
Keywords: مهارکننده کالسیروئین موضعی; anogenital; carcinoma; clobetasol propionate; lichen sclerosus; tacrolimus; topical calcineurin inhibitor; vulva; VAS; visual analog scale; VAS-BP; visual analog scale burning/pain; VAS-PR; visual analog scale pruritus;
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
Keywords: مهارکننده کالسیروئین موضعی; atopic dermatitis; atopic eczema; OPA-15406; phosphodiesterase type 4 inhibitor; topical agents; topical calcineurin inhibitor; AD; atopic dermatitis; BSA; body surface area; DLQI; Dermatology Life Quality Index; EASI; Eczema Area and Severity Index; IGA;
Original articleThe efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs)
Keywords: مهارکننده کالسیروئین موضعی; excimer laser; laser; pimecrolimus; tacrolimus; topical calcineurin inhibitor; vitiligo; CI; confidence interval; EL; excimer laser/light; NB; narrowband; RCT; randomized controlled trial; RR; relative risk; UV; ultraviolet;
Topical tacrolimus treatment does not facilitate photocarcinogenesis in cancer-prone mice
Keywords: مهارکننده کالسیروئین موضعی; Tacrolimus; Topical calcineurin inhibitor; UV-induced carcinogenesis; K5.Stat3C mouse; Atopic dermatitis;
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2009
Keywords: مهارکننده کالسیروئین موضعی; Dermatology; skin disease; urticaria; atopic dermatitis; anaphylaxis; allergy; hypersensitivity disorders; food; drug; insect venom; ACU; Acquired cold urticaria; AD; Atopic dermatitis; ADEH; Atopic dermatitis with history of eczema herpeticum; ADVN; Atop
The use of topical calcineurin inhibitors in dermatology: Safety concerns
Keywords: مهارکننده کالسیروئین موضعی; AD; atopic dermatitis; AE; adverse event; CTCL; cutaneous T-cell lymphoma; FDA; Food and Drug Administration; TCI; topical calcineurin inhibitor;
A clinician's paradigm in the treatment of atopic dermatitis
Keywords: مهارکننده کالسیروئین موضعی; AD; atopic dermatitis; BMV; betamethasone valerate; FDA; Food and Drug Administration; IFN-γ; interferon gamma; IgE; immunoglobulin E; PUVA; psoralen plus UVA; TCI; topical calcineurin inhibitor; UVA; ultraviolet A; UVB; ultraviolet B;
Mechanisms of action of topical therapies and the rationale for combination therapy
Keywords: مهارکننده کالسیروئین موضعی; AD; atopic dermatitis; AP-1; activator protein-1; GM-CSF; granulocyte-macrophage colony-stimulating factor; IκBα; inhibitory nuclear factor-kappa B alpha; IFN-γ; interferon gamma; IL; interleukin; NF-AT; nuclear factor of activated T cells; NF-κB; nuc
Corticosteroids: Options in the era of steroid-sparing therapy
Keywords: مهارکننده کالسیروئین موضعی; AD; atopic dermatitis; BMV; betamethasone valerate; HPA; hypothalamic-pituitary-adrenal; TCI; topical calcineurin inhibitor;
A novel foam vehicle for delivery of topical corticosteroids
Keywords: مهارکننده کالسیروئین موضعی; BMV; betamethasone valerate; CP; clobetasol propionate; HPLC; high-performance liquid chromatography; PEG; polyethylene glycol; TCI; topical calcineurin inhibitor;
Therapeutic options in the treatment of psoriasis and atopic dermatitis
Keywords: مهارکننده کالسیروئین موضعی; AD; atopic dermatitis; APC; antigen-presenting cell; FDA; Food and Drug Administration; ICAM; intracellular adhesion molecule; IFN-γ; interferon gamma; Ig; immunoglobulin; IL; interleukin; IL-2R; interleukin 2 receptor; IMP; inosine monophosphate; LFA; l